Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors: Results...
September 12 2011 - 7:10AM
Business Wire
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and
Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today
announced new analyses from the DURATION-3 and -4 trials
demonstrating patients treated with the investigational medication
BYDUREON™ (exenatide extended-release for injectable suspension)
experienced significant improvements in select cardiovascular risk
factors, in comparison to patients who received commonly prescribed
diabetes treatments. The analyses showed that patients receiving
BYDUREON for the treatment of type 2 diabetes experienced
improvements in composite endpoints related to body weight,
abnormal blood pressure and abnormal lipid levels. These findings
will be presented at the 47th European Association for the Study of
Diabetes Annual Meeting in Lisbon, Portugal.
“Patients with diabetes are at least twice as likely as people
without the disease to have heart disease or a stroke. Having other
chronic conditions including obesity, high blood pressure or high
cholesterol further increases this risk,” said James Malone, MD,
global exenatide medical director, Lilly Diabetes. “These data
underscore the need to consider not only glycemic control but also
the important role played by other medical conditions that are
common among patients with type 2 diabetes.”
Study Results:
Patients participating in the DURATION-3 study received BYDUREON
or Lantus® (insulin glargine) in addition to metformin or metformin
plus a sulfonylurea. Interim results from the study’s ongoing
extension found that patients receiving BYDUREON and completing 84
weeks of therapy:
- Demonstrated statistically significant
reduction in body weight (vs. Lantus; treatment difference: 9.8
pounds).
Also, statistically significantly more patients in the BYDUREON
treatment arm:
- Met a composite endpoint of A1C
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Apr 2024 to May 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From May 2023 to May 2024